Self-assembled liposomal nanoparticles in photodynamic therapy

European Journal of Nanomedicine

Volumn 5, Issue 3, 2013, Pages 115-129

  Sadasivam, Magesh ^a   Avci, Pinar ^a,b,c   Gupta, Gaurav K ^a,b   Lakshmanan, Shanmugamurthy ^a   Chandran, Rakkiyappan ^a   Huang, Ying Ying ^a,b,d   Kumar, Raj ^a,b   Hamblin, Michael R ^a,b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d GUANGXI MEDICAL UNIVERSITY   (China)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

liposomes; nanoparticles; nanotechnology; photodynamic therapy; self assembly

Indexed keywords

BIOCOMPATIBILITY; DRUG DELIVERY; LIPOSOMES; MOLECULES; NANOPARTICLES; NANOTECHNOLOGY; PHOTOSENSITIZERS; SELF ASSEMBLY;

3-DIMENSIONAL STRUCTURES; DRUG DELIVERY VEHICLES; INTRAVENOUS INJECTIONS; LIPOSOMAL NANOPARTICLES; PHOTODYNAMIC THERAPY (PDT); REACTIVE OXYGEN SPECIES; SELF ASSEMBLED NANOPARTICLES; SELF ASSEMBLY PROCESS;

PHOTODYNAMIC THERAPY;

ANTIBODY; ENZYME TRIGGERED LIPOSOME; FOLATE TARGETED LIPOSOME; FUSOGENIC LIPOSOME; LIGAND; LIGHT SENSITIVE LIPOSOME; LIPOSOME; NANOPARTICLE; SELF ASSEMBLED LIPOSOMAL NANOPARTICLE; THERMO SENSITIVE LIPOSOME; UNCLASSIFIED DRUG;

ANTIGENICITY; CHEMICAL COMPOSITION; CIRCULATION TIME; CONFORMATION; DRUG RELEASE; DRUG TARGETING; HALF LIFE TIME; IN VITRO STUDY; LIGHT; LIPID BILAYER; LIPOPHILICITY; LIPOSOMAL DELIVERY; NANOTECHNOLOGY; PHOSPHOLIPID BILAYER; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; RETICULOENDOTHELIAL SYSTEM; REVIEW; SOLUBILITY;

EID: 84903691091     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2013-0010     Document Type: Review

References (109)

1. Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 1900;39:524-46.
2. Jesionek A, von Tappenier H. Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochneshr 1903;47:2042-4.
3. Peck GC, Mack HP, Holbrook WA. Use of hematoporphyrin fluorescence in biliary and cancer surgery. Ann Surg 1955;21:181-8.
4. Rassmussan-Taxdal DS, Ward GE, Figge FH. Fluorescence of human lymphatic and cancer tissues following high doses of intravenous hematoporphyrin. Cancer 1955;8:78-81.
5. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn Ther 2004;1:279-93. (Pubitemid 40460316)
6. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008;26:612-21.
7. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002;66:89-106. (Pubitemid 34240266)
8. Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV. Nanodrug applications in photodynamic therapy. Photodiagnosis Photodyn Ther 2011;8:14-29.
9. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011;44:1123-34.
10. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007;150:552-8. (Pubitemid 46355555)
11. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005;146:882-93. (Pubitemid 41622255)
12. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev 2008;60:1627-37.
13. Mann S. Self-assembly and transformation of hybrid nano-objects and nanostructures under equilibrium and non-equilibrium conditions. Nat Mater 2009;8:781-92.
14. Allain V, Bourgaux C, Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res 2012;40:1891-903.
15. Rajagopal K, Schneider JP. Self-assembling peptides and proteins for nanotechnological applications. 2004;14:480-6.
16. Liu T, Guo R. Preparation of a highly stable niosome and its hydrotrope-solubilization action to drugs. Langmuir 2005;21:11034-9. (Pubitemid 41775061)
17. Kurland NE, Kundu J, Pal S, Kundu SC, Yadavalli VK. Self-assembly mechanisms of silk protein nanostructures on two-dimensional surfaces. Soft Matter 2012;8:4952-9.
18. Chen Y, Liang G. Enzymatic self-assembly of nanostructures for theranostics. Theranostics 2012;2:139-47.
19. Blin JL, Imperor-Clerc M. Mechanism of self-assembly in the synthesis of silica mesoporous materials: in situ studies by X-ray and neutron scattering. Chem Soc Rev 2013;42:4071-82.
20. Lee W, Amini H, Stone HA, Di Carlo D. Dynamic self-assembly and control of microfluidic particle crystals. Proc Natl Acad Sci USA 2010;107:22413-8.
21. Giacometti A, Lado F, Largo J, Pastore G, Sciortino F. Effects of patch size and number within a simple model of patchy colloids. J Chem Phys 2010;132:174110.
22. Kern N, Frenkel D. Fluid-fluid coexistence in colloidal systems with short-ranged strongly directional attraction. J Chem Phys 2003;118:9882-9.
23. Li L, Moon H, Park J-Y, Heo Y, Choi Y, Tran T, et al. Heparin-based self-assembled nanoparticles for photodynamic therapy. Macromol Res 2011;19:487-94.
24. Li F, Na K. Self-assembled Chlorin e6 conjugated chondroitin sulfate nanodrug for photodynamic therapy. Biomacromolecules 2011;12:1724-30.
25. Gooding JJ, Mearns F, Yang W, Liu J. Self-assembled monolayers into the 21st century: recent advances and applications. Electroanalysis 2003;15:81-96.
26. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60. (Pubitemid 40282557)
27. Mezei M, Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration: gel dosage form. J Pharm Pharmacol 1982;34:473-4. (Pubitemid 12082555)
28. Goyal P, Goyal K, Vijaya Kumar SG, Singh A, Katare OP, Mishra DN. Liposomal drug delivery systems-clinical applications. Acta Pharm 2005;55:1-25. (Pubitemid 40562616)
29. Joo K-I, Xiao L, Liu S, Liu Y, Lee C-L, Conti PS, et al. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials 2013;34:3098-109.
30. Nombona N, Maduray K, Antunes E, Karsten A, Nyokong T. Synthesis of phthalocyanine conjugates with gold nanoparticles and liposomes for photodynamic therapy. J Photochem Photobiol B 2012;107:35-44.
31. Jin CS, Zheng G. Liposomal nanostructures for photosensitizer delivery. Lasers Surg Med 2011;43:734-48.
32. Derycke AS, de Witte PA. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004;56:17-30. (Pubitemid 38045422)
33. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997;154:123-40. (Pubitemid 27351317)
34. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004;3:436-50. (Pubitemid 38855151)
35. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 2003;63:8126-31. (Pubitemid 37549458)
36. Bressler NM, Treatment of age-related macular degeneration with photodynamic therapy study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207. (Pubitemid 32147926)
37. Liu R. Methods of making liposomes containing hydromonobenzoporphyrin photosensitizer. US Patent 5707608. 1998.
38. Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta Ophthalmol 2009;87:118-32.
39. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology 2003;110:1315-20. (Pubitemid 36842464)
40. Parodi MB, Iacono P, Spasse S, Ravalico G. Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am J Ophthalmol 2006;141: 123-8. (Pubitemid 43016181)
41. Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 2003;241: 899-906. (Pubitemid 37527049)
42. Hogan A, Behan U, Kilmartin DJ. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 2005;89:1109-11. (Pubitemid 41224455)
43. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008;53:121-38. (Pubitemid 351381556)
44. Gross N, Ranjbar M, Evers C, Hua J, Martin G, Schulze B, et al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis 2013;19:54-61.
45. Isele U, van Hoogevest P, Leuenberger H, Capraro HG, Schieweck K. Pharmaceutical development of CGP 55847: a liposomal Zn-phthalocyanine formulation using a controlled organic solvent dilution method. Proc SPIE 1994;2078:397.
46. Ochsner M. Light scattering of human skin: a comparison between zinc (II)-phthalocyanine and photofrin II. J Photochem Photobiol B 1996;32:3-9.
47. Nyst HJ, Wildeman MA, Indrasari SR, Karakullukcu B, van Veen RL, Adham M, et al. Temoporfin mediated photodynamic therapy in patients with local persistent and recurrent nasopharyngeal carcinoma after curative radiotherapy: a feasibility study. Photodiagnosis Photodyn Ther 2012;9:274-81.
48. Durbec M, Cosmidis A, Fuchsmann C, Ramade A, Ceruse P. Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx. Eur Arch Oto-Rhino-L 2013;270:1433-9.
49. Betz CS, Rauschning W, Stranadko EP, Riabov MV, Volgin VN, Albrecht V, et al. Long-term outcomes following Foscan(R)-PDT of basal cell carcinomas. Lasers Surg Med 2012;44:533-40.
50. Tan IB, Dolivet G, Ceruse P, Vander Poorten V, Roest G, Rauschning W. Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study. Head Neck 2010;32:1597-604.
51. Kiesslich T, Berlanda J, Plaetzer K, Krammer B, Berr F. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan-and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci 2007;6:619-27. (Pubitemid 46889468)
52. Garrier J, Bezdetnaya L, Barlier C, Grafe S, Guillemin F, D'Hallewin MA. Foslip(R)-based photodynamic therapy as a means to improve wound healing. Photodiagnosis Photodynamic Ther 2011;8:321-7.
53. de Visscher SA, Kascakova S, de Bruijn HS, van den Heuvel A, Amelink A, Sterenborg HJ, et al. Fluorescence localization and kinetics of mTHPC and liposomal formulations of mTHPC in the window-chamber tumor model. Lasers Surg Med 2011;43: 528-36.
54. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-5. (Pubitemid 32183021)
55. Bedu-Addo FK, Tang P, Xu Y, Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharmaceut Res 1996;13:710-7.
56. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003;90:323-34. (Pubitemid 36859964)
57. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci 1991;88:11460-4. (Pubitemid 21916061)
58. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21. (Pubitemid 37361666)
59. Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, O'Kennedy R. Molecular and magnetic resonance imaging: the value of immunoliposomes. Adv Drug Deliv Rev 2009;61: 1402-11.
60. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997;54:8-14.
61. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, et al. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 2002;101:78-85. (Pubitemid 34833001)
62. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005;2:319-27. (Pubitemid 41282750)
63. Oku N, Saito N, Namba Y, Tsukada H, Dolphin D, Okada S. Application of long-circulating liposomes to cancer photodynamic therapy. Biol Pharm Bull 1997;20:670-3. (Pubitemid 27300344)
64. D'Hallewin MA, Kochetkov D, Viry-Babel Y, Leroux A, Werkmeister E, Dumas D, et al. Photodynamic therapy with intratumoral administration of Lipid-Based mTHPC in a model of breast cancer recurrence. Lasers Surg Med 2008;40:543-9.
65. Reshetov V, Zorin V, Siupa A, D'Hallewin MA, Guillemin F, Bezdetnaya L. Interaction of liposomal formulations of meta-tetra(hydroxyphenyl)chlorin (temoporfin) with serum proteins: protein binding and liposome destruction. Photochem Photobiol 2012;88:1256-64.
66. Compagnin C, Moret F, Celotti L, Miotto G, Woodhams JH, MacRobert AJ, et al. Meta-tetra(hydroxyphenyl)chlorin-loaded liposomes sterically stabilised with poly(ethylene glycol) of different length and density: characterisation, in vitro cellular uptake and phototoxicity. Photochem Photobiol Sci 2011;10:1751-9.
67. Petri A, Yova D, Alexandratou E, Kyriazi M, Rallis M. Comparative characterization of the cellular uptake and photodynamic efficiency of Foscan® and Fospeg in a human prostate cancer cell line. Photodiagnosis Photodynamic Ther 2012;9:344-54.
68. Bovis MJ, Woodhams JH, Loizidou M, Scheglmann D, Bown SG, MacRobert AJ. Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy. J Control Release 2012;157:196-205.
69. Sherifa G, Saad Zaghloul MA, Elsayed OF, Rueck A, Steiner R, Abdelaziz AI, Abdel-Kader MH. Functional characterization of Fospeg, and its impact on cell cycle upon PDT of Huh7 hepatocellular carcinoma cell model. Photodiagnosis Photodynamic Ther 2013;10:87-94.
70. Mueller A, O'Brien DF. Supramolecular materials via polymerization of mesophases of hydrated amphiphiles. Chem Rev 2002;102:727-57. (Pubitemid 35381632)
71. Regen SL, Singh A, Oehme G, Singh M. Polymerized phosphatidyl choline vesicles. Stabilized and controllable time-release carriers. Biochem Biophys Res Commun 1981;101:131-6.
72. Yavlovich A, Singh A, Tarasov S, Capala J, Blumenthal R, Puri A. Design of liposomes containing photopolymerizable phospholipids for triggered release of contents. J Therm Anal Calorim 2009;98:97-104.
73. Bisby RH, Mead C, Morgan CG. Wavelength-programmed solute release from photosensitive liposomes. Biochem Biophys Res Commun 2000;276:169-73.
74. Morgan CG, Bisby RH, Johnson SA, Mitchell AC. Fast solute release from photosensitive liposomes: an alternative to 'caged' reagents for use in biological systems. FEBS Lett 1995;375:113-6.
75. Thompson DH, Gerasimov OV, Wheeler JJ, Rui Y, Anderson VC. Triggerable plasmalogen liposomes: improvement of system efficiency. Biochim Biophys Acta 1996;1279:25-34. (Pubitemid 26067413)
76. Chowdhary RK, Green CA, Morgan CG. Dye-sensitized destabilization of liposomes bearing photooxidizable lipid head groups. Photochem Photobiol 1993;58:362-6.
77. Yavlovich A, Smith B, Gupta K, Blumenthal R, Puri A. Lightsensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol Membr Biol 2010;27:364-81.
78. Anderson VC, Thompson DH. Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid. Biochim Biophys Acta 1992;1109:33-42.
79. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008;58:97-110. (Pubitemid 351521865)
80. Andresen TL, Thompson DH, Kaasgaard T. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. Mol Membr Biol 2010;27:353-63.
81. Sarkar N, Banerjee J, Hanson AJ, Elegbede AI, Rosendahl T, Krueger AB, et al. Matrix metalloproteinase-assisted triggered release of liposomal contents. Bioconjug Chem 2008;19:57-64. (Pubitemid 351213835)
82. Monkkonen J, Urtti A. Lipid fusion in oligonucleotide and gene delivery with cationic lipids. Adv Drug Deliv Rev 1998;34:37-49. (Pubitemid 28464477)
83. Tu Y, Kim JS. A fusogenic segment of glycoprotein H from herpes simplex virus enhances transfection efficiency of cationic liposomes. J Gene Med 2008;10:646-54. (Pubitemid 351936537)
84. Metselaar JM, Mastrobattista E, Storm G. Liposomes for intravenous drug targeting: design and applications. Mini Rev Med Chem 2002;2:319-29.
85. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 2001;1513:193-206. (Pubitemid 32706417)
86. Kunisawa J, Masuda T, Katayama K, Yoshikawa T, Tsutsumi Y, Akashi M, et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release 2005;105:344-53. (Pubitemid 40941998)
87. Vanic Z, Barnert S, Suss R, Schubert R. Fusogenic activity of PEGylated pH-sensitive liposomes. J Liposome Res 2012;22:148-57.
88. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009;71:431-44.
89. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56:947-65. (Pubitemid 38520203)
90. Aicher A, Miller K, Reich E, Hautmann R. Photodynamic therapy of human bladder carcinoma cells in vitro with pH-sensitive liposomes as carriers for 9-acetoxy-tetra-n-propylporphycene. Urol Res 1994;22:25-32. (Pubitemid 24149217)
91. Qualls MM, Thompson DH. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholinefolate liposomes: intracellular localization and synergistic phototoxicity. Int J Cancer 2001;93:384-92. (Pubitemid 32592058)
92. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 2008;60:1193-208.
93. Rijcken CJ, Hofman J-W, van Zeeland F, Hennink WE, van Nostrum CF. Photosensitiser-loaded biodegradable polymeric micelles: Preparation, characterisation and in vitro PDT efficacy. J Control Release 2007;124:144-53. (Pubitemid 350101885)
94. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005;94:2135-46. (Pubitemid 41665275)
95. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93. (Pubitemid 40312593)
96. Sega EI, Low PS. Tumor detection using folate receptortargeted imaging agents. Cancer Metastasis Rev 2008;27:655-64.
97. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9.
98. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol 2004;66:1406-14. (Pubitemid 39564767)
99. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198-204. (Pubitemid 24237629)
100. Lee RJ, Wang S, Low PS. Measurement of endosome pH following folate receptor-mediated endocytosis. Biochim Biophys Acta 1996;1312:237-42. (Pubitemid 26246522)
101. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 2007;321:462-8. (Pubitemid 46624512)
102. Rui Y, Wang S, Low PS, Thompson DH. Diplasmenylcholinefolate liposomes: an efficient vehicle for intracellular drug delivery. J Am Chem Soc 1998;120:11213-8. (Pubitemid 28531061)
103. Garcia-Diaz M, Nonell S, Villanueva A, Stockert JC, Canete M, Casado A, et al. Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity? Biochim Biophys Acta 2011;1808:1063-71.
104. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60. (Pubitemid 40282557)
105. Mir Y, Elrington SA, Hasan T. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine. 2013 Feb 26. [Epub ahead of print].
106. Fabbrini M, Trachsel E, Soldani P, Bindi S, Alessi P, Bracci L, et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate. Int J Cancer 2006;118:1805-13. (Pubitemid 43376447)
107. Derycke AS, De Witte PA. Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. Int J Oncol 2002;20:181-7.
108. Gijsens A, Derycke A, Missiaen L, De Vos D, Huwyler J, Eberle A, et al. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 2002;101:78-85. (Pubitemid 34833001)
109. Ichikawa K, Hikita T, Maeda N, Yonezawa S, Takeuchi Y, Asai T, et al. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys Acta 2005;1669:69-74. (Pubitemid 40544523)